129 related articles for article (PubMed ID: 24309387)
21. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
22. [Tyrosine kinase inhibitors (TKI): a new revolution in the treatment of chronic myeloid leukemia (CML)].
Avilés-Vázquez S; Chávez-González A; Mayani H
Gac Med Mex; 2013; 149(6):646-54. PubMed ID: 24276188
[TBL] [Abstract][Full Text] [Related]
23. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
24. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
25. [Treatment of chronic myeloid leukemia with imatinib in the accelerated stage of the disease].
Bulum J; Labar B; Mikulić M; Bogdanić V; Sertić D; Nemet D; Krecak-Gverić V; Kovacević J; Serventi-Seiwerth R; Mrsić-Davidović S; Zadro R; Boban D
Lijec Vjesn; 2003; 125(7-8):176-9. PubMed ID: 14692090
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory.
Bouchet S; Titier K; Moore N; Lassalle R; Ambrosino B; Poulette S; Schuld P; Belanger C; Mahon FX; Molimard M
Fundam Clin Pharmacol; 2013 Dec; 27(6):690-7. PubMed ID: 23113675
[TBL] [Abstract][Full Text] [Related]
27. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Hochhaus A; Kreil S; Corbin AS; La Rosée P; Müller MC; Lahaye T; Hanfstein B; Schoch C; Cross NC; Berger U; Gschaidmeier H; Druker BJ; Hehlmann R
Leukemia; 2002 Nov; 16(11):2190-6. PubMed ID: 12399961
[TBL] [Abstract][Full Text] [Related]
28. Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients.
Mustjoki S; Richter J; Barbany G; Ehrencrona H; Fioretos T; Gedde-Dahl T; Gjertsen BT; Hovland R; Hernesniemi S; Josefsen D; Koskenvesa P; Dybedal I; Markevärn B; Olofsson T; Olsson-Strömberg U; Rapakko K; Thunberg S; Stenke L; Simonsson B; Porkka K; Hjorth-Hansen H;
Leukemia; 2013 Jul; 27(7):1520-6. PubMed ID: 23328954
[TBL] [Abstract][Full Text] [Related]
29. [Cytogenetic response as a marker of efficacy of chronic myeloid leukemia therapy with a BCR-ABL thyrosine kinase inhibitor glivek].
Turkina AG; Kruglov SS; Druzhkova GA; Domracheva EV; Zakharova AV; Vinogradova OIu; Sysoeva EP; Diachenko LV; Chelysheva EIu; Zakharova ES; Abakumov EM; Kolosheĭnova TI; Kolosova LIu; Ivanova TV; Zhuravlev VS; Nemchenko IS; Zingerman BV; Kurova ES; Triputen' NZ; Loriia SS; Kovaleva LG; Khoroshko ND
Ter Arkh; 2005; 77(7):42-7. PubMed ID: 16116908
[TBL] [Abstract][Full Text] [Related]
30. Current and emerging treatment options in chronic myeloid leukemia.
Jabbour E; Cortes JE; Giles FJ; O'Brien S; Kantarjian HM
Cancer; 2007 Jun; 109(11):2171-81. PubMed ID: 17431887
[TBL] [Abstract][Full Text] [Related]
31. Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia.
Ault P
Clin J Oncol Nurs; 2007 Feb; 11(1):125-9. PubMed ID: 17441403
[TBL] [Abstract][Full Text] [Related]
32. Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure.
Shih LY; Kuo MC; Kuo CY; Lin TH; Bai LY; Chen TY; Wang MC; Lin TL; Lan YJ; Chen CC; Yang Y; Hsiao PC; Lai CL; Chang CH; Lin TH
Leuk Res; 2013 Jan; 37(1):43-9. PubMed ID: 23062378
[TBL] [Abstract][Full Text] [Related]
33. Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib.
Defina M; Gozzetti A; Rondoni M; Aprile L; Ippoliti M; Chitarrelli I; Lauria F; Bocchia M
Leuk Res; 2010 Aug; 34(8):e215-6. PubMed ID: 20334915
[No Abstract] [Full Text] [Related]
34. Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia.
Steegmann JL; Moreno G; Aláez C; Osorio S; Granda A; de la Cámara R; Arranz E; Reino FG; Salvanés FR; Fernández-Rañada JM; Muñoz C
Haematologica; 2003 Jul; 88(7):762-8. PubMed ID: 12857554
[TBL] [Abstract][Full Text] [Related]
35. Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome.
Iurlo A; Nobili A; Latagliata R; Bucelli C; Castagnetti F; Breccia M; Abruzzese E; Cattaneo D; Fava C; Ferrero D; Gozzini A; Bonifacio M; Tiribelli M; Pregno P; Stagno F; Vigneri P; Annunziata M; Cavazzini F; Binotto G; Mansueto G; Russo S; Falzetti F; Montefusco E; Gugliotta G; Storti S; D'Addosio AM; Scaffidi L; Cortesi L; Cedrone M; Rossi AR; Avanzini P; Mauro E; Spadea A; Celesti F; Giglio G; Isidori A; Crugnola M; Calistri E; Sorà F; Rege-Cambrin G; Sica S; Luciano L; Galimberti S; Orlandi EM; Bocchia M; Tettamanti M; Alimena G; Saglio G; Rosti G; Mannucci PM; Cortelezzi A
Oncotarget; 2016 Nov; 7(48):80083-80090. PubMed ID: 27579540
[TBL] [Abstract][Full Text] [Related]
36. [Chronic myeloid leukemia: "archetype" of the impact of targeted therapies].
Nasr R; Bazarbachi A
Pathol Biol (Paris); 2012 Aug; 60(4):239-45. PubMed ID: 22743097
[TBL] [Abstract][Full Text] [Related]
37. Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era.
Malagola M; Breccia M; Skert C; Cancelli V; Soverini S; Iacobucci I; Cattina F; Liberati AM; Tiribelli M; Annunziata M; Trabacchi E; De Vivo A; Castagnetti F; Martinelli G; Fogli M; Stagno F; Pica G; Iurlo A; Pregno P; Abruzzese E; Pardini S; Bocchia M; Russo S; Pierri I; Lunghi M; Barulli S; Merante S; Mandelli F; Alimena G; Rosti G; Baccarani M; Russo D
Am J Hematol; 2014 Feb; 89(2):119-24. PubMed ID: 24122886
[TBL] [Abstract][Full Text] [Related]
38. Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy.
Aichberger KJ; Herndlhofer S; Agis H; Sperr WR; Esterbauer H; Rabitsch W; Knöbl P; Haas OA; Thalhammer R; Schwarzinger I; Sillaber C; Jäger U; Valent P
Eur J Clin Invest; 2007 Oct; 37(10):808-13. PubMed ID: 17727673
[TBL] [Abstract][Full Text] [Related]
39. Elderly CML patients' treatment: considering not only physician's judgment but also co-morbidity indexes.
Sánchez-Guijo F
Leuk Res; 2014 Oct; 38(10):1156-7. PubMed ID: 25113280
[No Abstract] [Full Text] [Related]
40. Charlson comorbidity index predicts poor outcome in CML patients treated with tyrosine kinase inhibitor.
Uemura M; Imataki O; Kawachi Y; Kawakami K; Hoshijima Y; Matsuoka A; Kadowaki N
Int J Hematol; 2016 Nov; 104(5):621-627. PubMed ID: 27492732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
